Meeting
2023 ASCO Annual Meeting
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
Authors
Aurélie Swalduz
Department of Medical Oncology, Centre Léon Bérard, Lyon, France
Aurélie Swalduz , Hubert Curcio , Bana Ambasager , Gabriel Le Moel , Didier Debieuvre , Jean Marc Dot , Michaël Duruisseaux , Pierre Fournel , Luc Odier , Sylvie Demolombe , Acya Bizieux-Thamany , Annie Peytier , Roland Schott , Stephane Hominal , Mathilde Donnat , Sandra Ortiz Cuaran , Camille Schiffler , Nitzan Rosenfeld , Pierre Saintigny , Maurice Perol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03721120
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9019)
DOI
10.1200/JCO.2023.41.16_suppl.9019
Abstract #
9019
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2020 ASCO Quality Care Symposium
Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).
First Author: Anik Patel